Welcome to the first newsletter of 2016. Hope your 2016 has gone off to flying start, and you have made some serious health commitments for this year.
As a new feature in this newsletter, we are highlighting important studies from the last several months - year, which are of interest to our patient population.
On the news front, from our practice, I was recently invited to deliver grand rounds to the Cedars-Sinai spine Institute. During this lecture, I highlighted the exciting biologic therapies that we have available for rheumatoid arthritis. However, we also highlighted the difficulties of these medications for spine surgery, I'm hopeful that this dialogue can lead to better care for rheumatoid arthritis patients who undergo spine surgery.
We have continued our collaboration with the Brigham & Women's Hospital, and have implemented objective data collection for our patients at the point of care, and using this objective data to make decisions about changing rheumatoid arthritis medications. This has been a very fruitful collaboration that has taught our office a lot about how to provide high quality care using objective measures to direct chronic disease care.
Our research program has also continued, and currently I am enrolling patients for a clinical trial of tocilizumab for the treatment of myositis. We have multiple clinical trials that are open and enrolling in lupus, and we're continuing to study the genes of patients in Sjogren's syndrome. If you're interested in participating, or know of someone who might be interested in participating in this cutting-edge research, please have them contact the office at 310-659-9959 or by e-mail at firstname.lastname@example.org.
Sincerely Swamy Venuturupalli, MD.